Clinical Trial Update: An Open-Label Study of E7974 Administered on Days 1, 8, and 15 of a 28-Day Cycle and Days 1 and 8 of a 21-Day Cycle in Patients With Solid Malignancies [Phase 1]

View source ↗

Summary

A Phase 1 open-label study evaluating E7974 given on two dosing schedules in patients with solid malignancies; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• E7974

Snippet

Sponsor: Eisai Inc. | Conditions: Solid Tumor Malignancies, Cancer | Phase 1 | Status: COMPLETED